Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms
Author
Gordon, David EHiatt, Joseph
Bouhaddou, Mehdi
Rezelj, Veronica V
Ulferts, Svenja
Braberg, Hannes
Jureka, Alexander S
Obernier, Kirsten
Guo, Jeffrey Z
Batra, Jyoti
Kaake, Robyn M
Weckstein, Andrew R
Owens, Tristan W
Gupta, Meghna
Pourmal, Sergei
Titus, Erron W
Cakir, Merve
Soucheray, Margaret
McGregor, Michael
Cakir, Zeynep
Jang, Gwendolyn
O'Meara, Matthew J
Tummino, Tia A
Zhang, Ziyang
Foussard, Helene
Rojc, Ajda
Zhou, Yuan
Kuchenov, Dmitry
Hüttenhain, Ruth
Xu, Jiewei
Eckhardt, Manon
Swaney, Danielle L
Fabius, Jacqueline M
Ummadi, Manisha
Tutuncuoglu, Beril
Rathore, Ujjwal
Modak, Maya
Haas, Paige
Haas, Kelsey M
Naing, Zun Zar Chi
Pulido, Ernst H
Shi, Ying
Barrio-Hernandez, Inigo
Memon, Danish
Petsalaki, Eirini
Dunham, Alistair
Marrero, Miguel Correa
Burke, David
Koh, Cassandra
Vallet, Thomas
Silvas, Jesus A
Azumaya, Caleigh M
Billesbølle, Christian
Brilot, Axel F
Campbell, Melody G
Diallo, Amy
Dickinson, Miles Sasha
Diwanji, Devan
Herrera, Nadia
Hoppe, Nick
Kratochvil, Huong T
Liu, Yanxin
Merz, Gregory E
Moritz, Michelle
Nguyen, Henry C
Nowotny, Carlos
Puchades, Cristina
Rizo, Alexandrea N
Schulze-Gahmen, Ursula
Smith, Amber M
Sun, Ming
Young, Iris D
Zhao, Jianhua
Asarnow, Daniel
Biel, Justin
Bowen, Alisa
Braxton, Julian R
Chen, Jen
Chio, Cynthia M
Chio, Un Seng
Deshpande, Ishan
Doan, Loan
Faust, Bryan
Flores, Sebastian
Jin, Mingliang
Kim, Kate
Lam, Victor L
Li, Fei
Li, Junrui
Li, Yen-Li
Li, Yang
Liu, Xi
Lo, Megan
Lopez, Kyle E
Melo, Arthur A
Moss, Frank R
Nguyen, Phuong
Paulino, Joana
Pawar, Komal Ishwar
Peters, Jessica K
Pospiech, Thomas H
Safari, Maliheh
Sangwan, Smriti
Schaefer, Kaitlin
Thomas, Paul V
Thwin, Aye C
Trenker, Raphael
Tse, Eric
Tsui, Tsz Kin Martin
Wang, Feng
Whitis, Natalie
Yu, Zanlin
Zhang, Kaihua
Zhang, Yang
Zhou, Fengbo
Saltzberg, Daniel
Hodder, Anthony J
Shun-Shion, Amber S
Williams, Daniel M
White, Kris M
Rosales, Romel
Kehrer, Thomas
Miorin, Lisa
Moreno, Elena
Patel, Arvind H
Rihn, Suzannah
Khalid, Mir M
Vallejo-Gracia, Albert
Fozouni, Parinaz
Simoneau, Camille R
Roth, Theodore L
Wu, David
Karim, Mohd Anisul
Ghoussaini, Maya
Dunham, Ian
Berardi, Francesco
Weigang, Sebastian
Chazal, Maxime
Park, Jisoo
Logue, James
McGrath, Marisa
Weston, Stuart
Haupt, Robert
Hastie, C James
Elliott, Matthew
Brown, Fiona
Burness, Kerry A
Reid, Elaine
Dorward, Mark
Johnson, Clare
Wilkinson, Stuart G
Geyer, Anna
Giesel, Daniel M
Baillie, Carla
Raggett, Samantha
Leech, Hannah
Toth, Rachel
Goodman, Nicola
Keough, Kathleen C
Lind, Abigail L
Klesh, Reyna J
Hemphill, Kafi R
Carlson-Stevermer, Jared
Oki, Jennifer
Holden, Kevin
Maures, Travis
Pollard, Katherine S
Sali, Andrej
Agard, David A
Cheng, Yifan
Fraser, James S
Frost, Adam
Jura, Natalia
Kortemme, Tanja
Manglik, Aashish
Southworth, Daniel R
Stroud, Robert M
Alessi, Dario R
Davies, Paul
Frieman, Matthew B
Ideker, Trey
Abate, Carmen
Jouvenet, Nolwenn
Kochs, Georg
Shoichet, Brian
Ott, Melanie
Palmarini, Massimo
Shokat, Kevan M
García-Sastre, Adolfo
Rassen, Jeremy A
Grosse, Robert
Rosenberg, Oren S
Verba, Kliment A
Basler, Christopher F
Vignuzzi, Marco
Peden, Andrew A
Beltrao, Pedro
Krogan, Nevan J
Date
2020-12-04Journal
Science (New York, N.Y.)Publisher
American Association for the Advancement of ScienceType
ArticleOther
Metadata
Show full item recordAbstract
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a grave threat to public health and the global economy. SARS-CoV-2 is closely related to the more lethal but less transmissible coronaviruses SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV). Here, we have carried out comparative viral-human protein-protein interaction and viral protein localization analyses for all three viruses. Subsequent functional genetic screening identified host factors that functionally impinge on coronavirus proliferation, including Tom70, a mitochondrial chaperone protein that interacts with both SARS-CoV-1 and SARS-CoV-2 ORF9b, an interaction we structurally characterized using cryo-electron microscopy. Combining genetically validated host factors with both COVID-19 patient genetic data and medical billing records identified molecular mechanisms and potential drug treatments that merit further molecular and clinical study.Rights/Terms
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.Identifier to cite or link to this item
http://hdl.handle.net/10713/14248ae974a485f413a2113503eed53cd6c53
10.1126/science.abe9403
Scopus Count
Related articles
- Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions.
- Authors: Gao X, Zhu K, Qin B, Olieric V, Wang M, Cui S
- Issue date: 2021 May 14
- Phosphorylation of SARS-CoV-2 Orf9b Regulates Its Targeting to Two Binding Sites in TOM70 and Recruitment of Hsp90.
- Authors: Brandherm L, Kobaš AM, Klöhn M, Brüggemann Y, Pfaender S, Rassow J, Kreimendahl S
- Issue date: 2021 Aug 26
- In-vitro acetylation of SARS-CoV and SARS-CoV-2 nucleocapsid proteins by human PCAF and GCN5.
- Authors: Hatakeyama D, Masuda T, Miki R, Ohtsuki S, Kuzuhara T
- Issue date: 2021 Jun 11
- SARS-CoV-2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms.
- Authors: O'Donoghue SI, Schafferhans A, Sikta N, Stolte C, Kaur S, Ho BK, Anderson S, Procter JB, Dallago C, Bordin N, Adcock M, Rost B
- Issue date: 2021 Sep
- SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO.
- Authors: Wu J, Shi Y, Pan X, Wu S, Hou R, Zhang Y, Zhong T, Tang H, Du W, Wang L, Wo J, Mu J, Qiu Y, Yang K, Zhang LK, Ye BC, Qi N
- Issue date: 2021 Feb 16
Related items
Showing items related by title, author, creator and subject.
-
Cardiac surgery in North America and coronavirus disease 2019 (COVID-19): Regional variability in burden and impactAd, Niv; Luc, Jessica G.Y.; Nguyen, Tom C.; Arora, Rakesh C.; Balkhy, Husam H.; Bender, Edward M.; Bethencourt, Daniel M.; Bisleri, Gianluigi; Boyd, Douglas; Chu, Michael W.A.; et al. (Elsevier Ltd., 2020-07-02)Objective: The coronavirus disease 2019 (COVID-19) pandemic has resulted in an increase in hospital resource utilization and the need to defer nonurgent cardiac surgery procedures. The present study aims to report the regional variations of North American adult cardiac surgical case volume and case mix through the first wave of the COVID-19 pandemic. Methods: A survey was sent to recruit participating adult cardiac surgery centers in North America. Data in regard to changes in institutional and regional cardiac surgical case volume and mix were analyzed. Results: Our study comprises 67 adult cardiac surgery institutions with diverse geographic distribution across North America, representing annualized case volumes of 60,452 in 2019. Nonurgent surgery was stopped during the month of March 2020 in the majority of centers (96%), resulting in a decline to 45% of baseline with significant regional variation. Hospitals with a high burden of hospitalized patients with COVID-19 demonstrated similar trends of decline in total volume as centers in low burden areas. As a proportion of total surgical volume, there was a relative increase of coronary artery bypass grafting surgery (high +7.2% vs low +4.2%, P =.550), extracorporeal membrane oxygenation (high +2.5% vs low 0.4%, P =.328), and heart transplantation (high +2.7% vs low 0.4%, P =.090), and decline in valvular cases (high –7.6% vs low –2.6%, P =.195). Conclusions: The present study demonstrates the impact of COVID-19 on North American cardiac surgery institutions as well as helps associate region and COVID-19 burden with the impact on cardiac surgery volumes and case mix.
-
The genomics of heart failure: design and rationale of the HERMES consortiumLumbers, R Thomas; Shah, Sonia; Lin, Honghuang; Czuba, Tomasz; Henry, Albert; Swerdlow, Daniel I; Mälarstig, Anders; Andersson, Charlotte; Verweij, Niek; Holmes, Michael V; et al. (Wiley-Blackwell, 2021-09-03)Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.
-
Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals.Winkler, Thomas W; Rasheed, Humaira; Teumer, Alexander; Gorski, Mathias; Rowan, Bryce X; Stanzick, Kira J; Thomas, Laurent F; Tin, Adrienne; Hoppmann, Anselm; Chu, Audrey Y; et al. (Springer Nature, 2022-06-13)Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (nDM = 178,691, nnoDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM.